Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.20p +0.19% 104.40p 104.50p 104.80p 106.10p 103.10p 103.50p 2,772,036 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 126.5 -40.1 -5.3 - 709.23

Vectura Share Discussion Threads

Showing 6076 to 6099 of 6100 messages
Chat Pages: 244  243  242  241  240  239  238  237  236  235  234  233  Older
DateSubjectAuthorDiscuss
18/9/2017
09:21
Not looking to good this morning one million trades and down 1.9p all by 9am
pooroldboy55
15/9/2017
08:42
I see all the big trades are going through as O trades anyone got any ideas why this would be?
pooroldboy55
13/9/2017
12:35
Another chunky buy. 70,000 shares at 98p. Should see this back at 108-110p in no time.
justiceforthemany
13/9/2017
09:49
Good to see the chairman putting his hand in his pocket. None of the directors' purchases have been huge but still quite significant sums. These purchases and the good news regarding Flutiform seem to have well and truly reversed the slide.
alexchry
13/9/2017
09:47
RNS: Chippenham, UK, 13 September 2017: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that on 12 September 2017, Bruno Angelici, Chairman and Person Discharging Managerial responsibility ("PDMR"), purchased 70,000 ordinary shares of 0.025 pence each in Vectura Group plc. Following the purchase, the total number of ordinary shares in the Company held by Bruno Angelici is 162,903.
citytrader66
12/9/2017
21:36
I think the purchases were instigated by the Advair generic position which was leaked about a month ago, post interims was the earliest they could buy, the final 20 p fall did them no harm!
diesel
12/9/2017
21:16
08 no problems, But maybe the board have manipulated the stock by kitchen sinking the result then purchasing more on the way down?
dp1umb
12/9/2017
20:32
Sorry misunderstanding. I did not wanted to imply that they should have waited with news. My understanding is that such a news needs to be made public as soon it is officially signed by all involved parties. But was it necessary to sign something like this on this date? Probably I oversee here something, than my apologies.
0815exitstrategy
12/9/2017
19:02
Will be interesting to see what happens when this reaches 110p, will it pause for breath or push through, remember we have been given a clear signal that the Advair generic will make it to market, when not if....
diesel
12/9/2017
16:37
The clue is in the R of an RNS.
dp1umb
12/9/2017
16:36
O8 and that's called insider trading!
dp1umb
12/9/2017
16:06
Vec really needs work on their communication skills. If they would have anounced the new Tiotropium development program with Pulmatrix today or tomorrow (and not on the 6th of Sep.), it would have had much more impact.
0815exitstrategy
12/9/2017
13:31
Sikhthetech-it is old news, it was released yesterday so should have had an impact this morning not later on in the day. I just hope it's a slow burner and we get a steady rise in the share price
alexchry
12/9/2017
13:24
next resistance around 108p! hold for gold! 🍷
citytrader66
12/9/2017
12:58
Good news, would have thought a better reaction.. Let's see what happens when the US markets open...
sikhthetech
12/9/2017
12:54
Directors buy is only the monthly 158 shares buy of the FD. ;-)
0815exitstrategy
12/9/2017
12:45
shorters keeping a lid on it me thinks. but will they be able to keep share price down this afternoon when buying pressure increases?? 110p possible today.
citytrader66
12/9/2017
12:41
Spike to 102p on the RNS. Back over a £. More Director buys also by FD. Hope to be back at 108-110p near term.
justiceforthemany
12/9/2017
12:36
RNS - Mundipharma presents positive findings at ERS 2017 👍
citytrader66
11/9/2017
23:13
british bulls BUY signal posted today. right on the money here guys 🍷🍷🍷🍷 7863;🍷Ӿ63;🍷🍷;
citytrader66
11/9/2017
17:10
One more positive RNS and I think we can finally pull out of this bear run .
dp1umb
11/9/2017
17:10
One more positive RNS and I think we can finally pull out of this bear run .
dp1umb
11/9/2017
16:58
Largest Ever flutiform® Study Confirms Effectiveness and Tolerability in Real-world Clinical Practice: Findings from AffIRM Study to be Presented at ERS 2017 PR Newswire CAMBRIDGE, England, September 11, 2017 CAMBRIDGE, England, September 11, 2017 /PRNewswire/ -- First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New real-world data to be presented at the European Respiratory Society (ERS) annual congress in Milan, Italy, will show that the proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI (pressurised metered dose inhaler) compared with baseline.[1] flutiform (fluticasone propionate/formoterol) is indicated for use as a maintenance treatment for asthma patients aged 12 years and older where ICS/LABA therapy is appropriate. "This large study further extends the body of evidence for flutiform, demonstrating its safety and effectiveness profile in patients in real life clinical practice with improved asthma control and a reduction in exacerbations compared with baseline," commented Professor David Price, Chair of Primary Care Respiratory Medicine at the University of Aberdeen, Aberdeen, UK. "Real-world evidence like this is essential to complement data from randomised controlled trials (RCTs) by evaluating outcomes in asthma patients in everyday clinical practice, as RCTs investigate a subgroup of the asthma population and adherence tends to be unusually high." Assessment of fluticasone propionate/formoterol In Real life Maintenance treatment (AffIRM) is the largest study to date of flutiform, with over 2,500 patients enrolled, and is part of Affinity, Mundipharma's international collaborative research programme for flutiform. In this one-year, non-interventional study of 2,539 asthma patients, more than two thirds of patients had switched from another ICS/LABA (either a fixed dose combination or free combination of ICS plus LABA).[1] The safety profile of flutiform pMDI in practice was consistent with that demonstrated in clinical trials. Secondary analyses demonstrated that the proportion of patients with controlled asthma increased from 29.4% at baseline to 67.4% (last observation carried forward) and the mean total Asthma Control Test score increased from 16.3 to 20.4.[1] In the year prior to enrolment, 64.2% patients were free from severe asthma exacerbations compared with 90.2% during the study period. flutiform pMDI was associated with improvements from baseline in Asthma Quality of Life scores, adherence and physician/patient satisfaction.[1] Sub-optimal asthma control remains a major problem in Europe, with many patients experiencing largely preventable symptoms that disrupt their daily lives.[2] Research suggests that only 20% of patients in Europe have controlled asthma according to the GINA definition.[2] In addition, poor or improper inhaler technique in asthma patients can lead to critical inhaler errors and are associated with reduced disease control,[3],[4] worse asthma outcomes[5] and an increase in hospital visits.[3] For further information, please visit: hxxp://www.mundipharma.com/Press/RespiratoryResources/background hxxp://www.flutiform.com/medical-media/resource-centre About the Mundipharma network The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. For more information please visit: hxxp://www.mundipharma.com. About flutiform In Europe, flutiform is licensed for the regular treatment of asthma when use of a combination product (an inhaled corticosteroid [ICS] and a long-acting β2-agonist [LABA]) is appropriate: for patients not adequately controlled with an ICS and an 'as required' inhaled short-acting β2-agonist or for patients already adequately controlled on both an ICS and a LABA. It is available in countries across Europe including the UK, Germany, France, Spain, Netherlands and Italy. flutiform is available in 50/5μg and 125/5μg strengths for adults and adolescents; 250/10μg strength for adults only.[6] About Asthma Asthma is a chronic inflammatory disorder of the airways which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Patients with poorly managed asthma are at an increased risk of exacerbations, hospitalisation and death. Poorly managed asthma can also have a huge impact on a person's quality of life and day-to-day activities.[7] About Vectura Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With its extensive range of device and formulation technologies, integrated capabilities and collaborations, Vectura is a leader in the development of inhalation products, increasing its ability to help patients suffering from respiratory diseases. Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams. The group has a diverse portfolio of drugs in clinical development, including a number of novel and generic programmes which are partnered with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork along with two wholly owned nebulised development programmes. References: 1. Backer V, et al. Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma. Abstract presented at European Respiratory Society (ERS) annual congress, Milan, Italy 2017 September 9- 13 [PA4037]. 2. Price, D., Fletcher, M., van der Molen, T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Prim Care Respir J 2014;24:14009-. doi:10.1038/npjpcrm.2014.9. 3. Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013;9(1):8. 4. Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma . 2014;51(4):429-34. 5. Price D, et al. "Inhaler errors in the CRITIKAL Study: type, frequency and association with asthma outcomes". Journal of Allergy and Clinical Immunology: In Practice. 2017;5(4):1071-1081 6. flutiform SmPC 7. European Respiratory Society. The European Lung White Book. 2013 Job code: MINT/RESP-17013 Date of preparation: September 2017
a1ord53
11/9/2017
13:43
Surely now would be a very good time for some share buybacks. I believe a resolution for this was passed at the AGM. If they aren't going to do them now then I'm not sure when they ever would.
gbcol
Chat Pages: 244  243  242  241  240  239  238  237  236  235  234  233  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170920 03:56:15